Lecap Asset Management Ltd. Sells 6,323 Shares of Gilead Sciences, Inc. $GILD

Lecap Asset Management Ltd. trimmed its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 68.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,928 shares of the biopharmaceutical company’s stock after selling 6,323 shares during the period. Lecap Asset Management Ltd.’s holdings in Gilead Sciences were worth $325,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its holdings in Gilead Sciences by 314.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock valued at $1,647,484,000 after buying an additional 11,156,382 shares in the last quarter. Nuveen LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at $620,415,000. Kingstone Capital Partners Texas LLC bought a new stake in Gilead Sciences in the second quarter worth $238,083,000. Los Angeles Capital Management LLC raised its stake in Gilead Sciences by 422.6% during the first quarter. Los Angeles Capital Management LLC now owns 2,523,036 shares of the biopharmaceutical company’s stock valued at $282,706,000 after purchasing an additional 2,040,261 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company’s stock valued at $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on GILD shares. UBS Group boosted their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Truist Financial upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $108.00 to $127.00 in a report on Friday, August 8th. Daiwa Capital Markets raised shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price target for the company in a research note on Tuesday, August 19th. Dbs Bank raised shares of Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Saturday, September 27th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $117.17.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the completion of the transaction, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at approximately $69,016,306.50. The trade was a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the sale, the insider owned 114,168 shares of the company’s stock, valued at $13,532,333.04. This trade represents a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $112.69 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The stock’s fifty day moving average price is $114.34 and its 200-day moving average price is $109.92. The firm has a market cap of $139.83 billion, a P/E ratio of 22.45, a P/E/G ratio of 0.75 and a beta of 0.34. Gilead Sciences, Inc. has a 12 month low of $83.98 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. The company had revenue of $7.08 billion for the quarter, compared to analysts’ expectations of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 dividend on an annualized basis and a yield of 2.8%. Gilead Sciences’s payout ratio is 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.